APRE
Aprea Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.14 / 10
Netural
With a fund flow rating of 7.54/10, the stock shows robust fund flow characteristics. Supportive momentum from overall, block, Large, and Extra-large trends is partially offset by concerning Small and Medium patterns, pointing to positive capital flow trajectory. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(100.0%) across 1 coverage providers, supported by 2.75 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-29
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of APRE?
- APRE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.14/10 (Netural).
